BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $30,593,235 | +159.9% | 1,160,153 | +69.5% | 0.01% | +166.7% |
Q2 2023 | $11,772,866 | +1232.0% | 684,469 | +1184.0% | 0.00% | – |
Q1 2023 | $883,846 | +172.1% | 53,308 | +25.1% | 0.00% | – |
Q4 2022 | $324,818 | -89.8% | 42,627 | -86.6% | 0.00% | -100.0% |
Q3 2022 | $3,170,000 | +708.7% | 318,882 | +638.0% | 0.00% | – |
Q2 2022 | $392,000 | -12.7% | 43,209 | -2.2% | 0.00% | – |
Q1 2022 | $449,000 | -43.7% | 44,190 | -7.6% | 0.00% | – |
Q4 2021 | $798,000 | -67.8% | 47,839 | -9.5% | 0.00% | -100.0% |
Q3 2021 | $2,478,000 | -12.9% | 52,866 | +13.3% | 0.00% | 0.0% |
Q2 2021 | $2,845,000 | +88.8% | 46,659 | +90.6% | 0.00% | – |
Q1 2021 | $1,507,000 | -42.0% | 24,474 | -33.0% | 0.00% | -100.0% |
Q4 2020 | $2,598,000 | +1070.3% | 36,532 | +519.1% | 0.00% | – |
Q3 2020 | $222,000 | -21.8% | 5,901 | -39.7% | 0.00% | – |
Q1 2020 | $284,000 | +18.3% | 9,792 | +42.9% | 0.00% | – |
Q4 2019 | $240,000 | – | 6,851 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |